Journal Article

Combinations of Single Chain Variable Fragments From HIV Broadly Neutralizing Antibodies Demonstrate High Potency and Breadth

Wagh, Kshitij, Moore, Penny L., van Dorsten, Rebecca T., Morris, Lynn

2021

Overview

Broadly neutralizing antibodies (bNAbs) are currently being assessed in clinical trials for their ability to prevent HIV infection. Single chain variable fragments (scFv) of bNAbs have advantages over full antibodies as their smaller size permits improved diffusion into mucosal tissues and facilitates vector-driven gene expression. We have previously shown that scFv of bNAbs individually retain significant breadth and potency. Here we tested combinations of five scFv derived from bNAbs CAP256-VRC26.25 (V2-apex), PGT121 (N332-supersite), 3BNC117 (CD4bs), 8ANC195 (gp120-gp41 interface) and 10E8v4 (MPER). Either two or three scFv were combined in equimolar amounts and tested in the TZM-bl neutralization assay against a multiclade panel of 17 viruses. Experimental IC 50 and IC 80 data were compared to predicted neutralization titers based on single scFv titers using the Loewe additive and the Bliss-Hill model. Like full-sized antibodies, combinations of scFv showed significantly improved potency and breadth compared to single scFv. Combinations of two or three scFv generally followed an independent action model for breadth and potency with no significant synergy or antagonism observed overall although some exceptions were noted. The Loewe model underestimated potency for some dual and triple combinations while the Bliss-Hill model was better at predicting IC 80 titers of triple combinations. Given this, we used the Bliss-Hill model to predict the coverage of scFv against a 45-virus panel at concentrations that correlated with protection in the AMP trials. Using IC 80 titers and concentrations of 1μg/mL, there was 93% coverage for one dual scFv combination (3BNC117+10E8v4), and 96% coverage for two of the triple combinations (CAP256.25+3BNC117+10E8v4 and PGT121+3BNC117+10E8v4). Combinations of scFv, therefore, show significantly improved breadth and potency over individual scFv and given their size advantage, have potential for use in passive immunization.

• Publisher: Frontiers Media SA,Frontiers Research Foundation,Frontiers Media S.A
• Subject: 60 APPLIED LIFE SCIENCES / Acquired immune deficiency syndrome / AIDS / Antibodies / broadly neutralizing antibodies / Broadly Neutralizing Antibodies - genetics / Broadly Neutralizing Antibodies - metabolism / Clinical trials / Cloning / combinations of scFv / Gene expression / Genetic Engineering / Glycerol / Glycoprotein gp120 / Glycoprotein gp41 / HEK293 Cells / HIV / HIV Antibodies - genetics / HIV Antibodies - metabolism / HIV Envelope Protein gp160 - genetics / HIV Infections - immunology / HIV prevention / HIV-1 - physiology / Human immunodeficiency virus / Humans / Immunization, Passive / Immunology / Molecular weight / Neutralization Tests / Plasmids / Proteins / single chain variable fragments / Single-Chain Antibodies - genetics / Viruses